Skip to main content
Publications
Layton JB , Lindaas A, Muthuri S, Lloyd PC, Richey MM, Gruber JF, Clarke TC, Kowarski L, McKillop M, Fisher S, Lyu H, Cheng A, Bui C , Duenas PF, Chen Y, Beers JB, Forshee RA, Anderson SA, Burrell T, Chillarige Y, Anthony MS , Shoaibi A. Risk of cardiovascular adverse events after COVID-19 diagnosis in the United States . Poster presented at the 2024 ISPE Annual Meeting; August 28, 2024. Berlin, Germany.
Weibel D, De Luise C, Cid Royo A, Ryan O, Vaz T, Aguado J , Marsal J , Garcia de Albeniz Martinez X , Weinrib R , Yefimenko N, Pala E, Poblador-Plou B, Gimeno-Miguel A, Santos-Mejias A, Marconi E, Barbieri E, Stona L, Lysen T, Roy D, Hyeraci G, Girardi A, Lupattelli A, Desalegn AA, Villalobos F, Bissacco CA, Kendrick K, Garg R, Rubino H, Sturkenboom MCJM, Arana A . Interim results from the VAC4EU Post-Authorization Safety Study (PASS) among recipients of the Pfizer-BioNTech COVID-19 (Comirnaty®) vaccine in Europe . Poster presented at the 2024 ISPE Annual Meeting; August 27, 2024. Berlin, Germany.
Ahmadizar F, Fortuny J , Royo AC, Plana E , Weinrib R , Garcia Esteban R , Boric K , Yefimenko N, Haugh M, Carreras JJ, Urchueguia-Fornes A, Correcher E, van den Berg JM, Lysen T, Villalobos F, Bissacco CA, Newbern EC, Willame C, Praet N, Sturkenboom MCJM. Safety of the Janssen COVID-19 vaccine (JCOVDEN) using VAC4EU European healthcare data sources: methods and results of the second study feasibility assessment . Poster presented at the 2024 ISPE Annual Meeting; August 27, 2024. Berlin, Germany.
Layton JB , Peetluk LS, Lloyd PC, Jiao Y, Djibo DA, Deng J, Gruber JF, Ogilvie RP, Parambi R, Miller M, Song J, Weatherby LB, Bell EJ, Lo AC, Hervol JR, Wernecke M, Cho S, Wong H-L, Clarke TC, Bui CL , Stone A, Tarazi W, Deshazo J, Forshee RA, Anderson SA, Seeger JD, Amend KL, MaMahill-Walraven CN, Chillarige Y, Yang GW, Anthony MS , Shoaibi A. Effectiveness over time of a complete primary series of the original, monovalent COVID-19 vaccines among adults aged 18-64 years in the United States . Poster presented at the 2024 ISPE Annual Meeting; August 27, 2024. Berlin, Germany.
Shah HA, Herrera-Restrepo O, Jutlla G, Carrico J, Hicks K , Kuylen E, Begum S, Clements D, Burman C, Sohn WY, Kocaata Z. Public health impact of MENABCWY vaccination in adolescents and MENB vaccination in infants in the United States . Poster presented at the 42nd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2024; May 20, 2024. Copenhagen, Denmark.
Sinclair G, Sension M, Dretler A, Schneider S, Schubert C, Merrill D, Richardson D , Sherif B , Zografos L , Garris C. Clinical outcomes at month 6 after initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world study (BEYOND) . Poster presented at the IDWeek 2023; October 13, 2023. Boston, MA.
Dandachi D, Cunningham D, Valenti W, Phoenix J, Nguyen K, Teichner P, Jean-Louis A, Reynolds M , Richardson D , Garris C. Perspectives of people with HIV (PWH) 6 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND) . Poster presented at the IDWeek 2023; October 13, 2023. Boston, MA.
Ghaswalla P, Hitchens A , Candrilli SD , Carrico J, Hicks KA , Wilson E, Mehta D, Panozzo CA. Prevalence of underlying conditions associated with higher risk for severe RSV, influenza, or COVID-19 in adults in the United States, 2017-2018 . Poster presented at the IDWeek 2023; October 12, 2023. Boston, MA.
Ogilvie RP, Layton JB , Wong HL, Jiao Y, Parambi RJ, Deng J, Miller M, Song J, Lloyd PC, Weatherby L, Peetluk LS, Bell EJ, Yang G, Amend KL, Kawai A , Lo AC, Matuska K, Wernecke M, Gruber JF, Clarke TC, Forshee RA, Anderson SA, Anthony MS , Chillarige Y, Seeger JD, Shoaibi A. Effectiveness of BNT162b2 COVID-19 vaccine in US children aged 5-17 years . Presented at the 39th ICPE Annual Conference; August 26, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):78. doi: 10.1002/pds.5687
Layton JB , Peetluk LS, Wong H, Jiao Y, Ogilvie RP, Miller M, Glazier-Essalmi A, Parambi RJ, Song J, Garcia de Albeniz Martinez X , Lloyd PC, Lo A, Kawai A , Weatherby L, Bell EJ, Yang G, Amend KL, Gruber JF, Clarke TC, Forshee RA, Anderson SA, Wernecke M, Matuska K, Chillarige Y, Anthony M , Seeger JD, Shoaibi A. Effectiveness of monovalent COVID-19 booster/additional vaccine doses in the United States . Presented at the 39th ICPE Annual Conference; August 27, 2023. Halifax, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2023 Oct 12; 32(S1):608. doi: 10.1002/pds.5687
Sung A, Houghton K , Cornely OA, Neofytos D, Pagliuca A, Capparella MR, Aguado J , Jimenez M , Gheorghe M. Effectiveness, safety, and patterns of real-world isavuconazole use—a retrospective medical record review study of patients with invasive aspergillosis . Poster presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023; April 15, 2023. Copenhagen, Denmark.
Hsu RK, Phoenix J, Sinclair GI, Gupta SK, Puga A, Nguyen K, Schubert CK, Merrill D, Richardson D , Nelson K , Reynolds M , Zografos L , Jean-Louis A, Garris C. US Healthcare Provider Perspectives on the initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world study (BEYOND) . Poster presented at the IDWeek 2022 Conference; October 21, 2022. Washington, DC.
Garcia de Albeniz X , Polo R, Teran C, Morales M, Rial-Crestelo D, Garcinuno MA, Garcia del Toro M, Hita C, Gomez-Sirvent JL, Buzon L, Diaz de Santiago A, Perez JL, Sanz J, Bachiller P, Martinez E, Diaz-Brito V, Masia M, Hernandez-Torres A, Guerra J, Arazo P, Arribas J, Martinez de Salazar P, Moreno S, Hernan MA, del Amo J. Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workers. A randomized clinical trial . Poster presented at the 2022 ICPE Conference; August 2022. Copenhagen, Denmark.
Osborne R, Nelson L , Fehnel S , Williams N, Bender RH, Ziemiecki R , Gymnopoulou E, De Paepe E, Norcross L , Heijnen E, Ispas G, Cheret A, Comeaux C, Callendret B, Vandendijck Y, Chan E, Scott J. Measurement of symptoms in respiratory syncytial virus–infected adults: meaningful within-patient change thresholds for the respiratory infection intensity and impact questionnaire (RiiQ) . Poster presented at the 8th ESWI Influenza Conference Scientific and SPI Virtual Programme; December 4, 2021.
Johannes C , Layton JB , Beachler DC, Ziemiecki RM , Li L, Danysh HE , Dinh J, Hunt PR, Karlsson C, Chen H, Gilsenan A . Risk of severe complications of urinary tract infection in real-world use of dapagliflozin . Poster presented at the 2021 Virtual American Diabetes Association 81st Scientific Session; June 25, 2021.
Osborne RH, Nelson L , Elsworth GR, Fehnel S , Williams N, Bender RH, Ziemiecki R , Gymnopoulou E, De Paepe E, Norcross L , Heijnen E, Ispas G, Cheret A, Comeaux C, Chan E, Scott JA. Psychometric evaluation of the Respiratory Infection Intensity and Impact Questionnaire Version 2 (RiiQTMv2) symptom scores for respiratory syncytial virus . Poster presented at the Virtual ISPOR 2021 Conference; May 2021.
Layton JB , Zhou CK, Danysh HE , Bleachler DC, Ziemiecki R , Dinah J, Yin R, Calingaert B , Hunt PR, Gilsenan AW , Johannes CW . Identifying cohorts of patients with type 2 diabetes mellitus initiating dapagliflozin in three data sources . Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Dinh J, Danysh HE , Johannes C , Gutierrez L , Schmid R, Arana A , Kaye JA, Pladevall-Vila M , Garcia de Albeniz X , Hunt PR, Gilsenan A , Beachler DC, Ke Zhou C. Description of acute kidney injury and breast cancer outcome validation processes across three databases . Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.